Iovance Biotherapeutics (NASDAQ:IOVA) Announces Quarterly Earnings Results, Meets Estimates

Iovance Biotherapeutics (NASDAQ:IOVA) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.26) EPS for the quarter, meeting the consensus estimate of ($0.26), Zacks reports. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. Iovance Biotherapeutics updated its FY 2025 guidance to EPS.

Iovance Biotherapeutics Trading Down 1.7 %

NASDAQ IOVA traded down $0.09 on Thursday, reaching $5.26. 11,385,051 shares of the stock were exchanged, compared to its average volume of 8,530,706. Iovance Biotherapeutics has a one year low of $5.05 and a one year high of $18.33. The firm has a market capitalization of $1.60 billion, a PE ratio of -3.53 and a beta of 0.54. The company’s 50-day simple moving average is $6.31 and its two-hundred day simple moving average is $8.64.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on IOVA. Piper Sandler lowered their price objective on shares of Iovance Biotherapeutics from $10.00 to $7.50 and set a “neutral” rating for the company in a report on Friday, January 31st. HC Wainwright reissued a “buy” rating and set a $32.00 price objective on shares of Iovance Biotherapeutics in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $21.07.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.